Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Aberrant DNA Methylation Maker for Predicting Metachronous Recurrence After Endoscopic Resection of Gastric Neoplasms

NCT04830618 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT04830618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04830618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Aberrant DNA Methylation Maker for Predicting Metachronous Recurrence After Endoscopic Resection of Gastric Neoplasms
Lead sponsor
Seoul National University Hospital
Phase
Observational
Overall status
Completed
Start date
September 11, 2012
Completion date
December 31, 2020
Enrollment
300 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

aberrant dna methylation, gastric cancer, gastric neoplasm, metachronous neoplasm